CNOverview
Tyrosine kinase inhibitors (TKIs) have become a critical component of first-line treatment for chronic myeloid leukemia (CML). However, some patients still develop primary or secondary resistance, with BCR-ABL1 kinase domain mutations being the main mechanism of resistance. Studies show that more than half of CML patients resistant to imatinib, nilotinib, or dasatinib test positive for BCR::ABL1 kinase domain mutations. Consequently, both ELN and NCCN guidelines recommend mutation testing when CML patients exhibit suboptimal response or treatment failure.
